Description

Epaviten 6 ampoules + 6 vials

The pharmacological properties of the drug are reflected in the actions of its components. Ascorbic acid slows down the excretion of barbiturates, sulfonamides, and salicylates. Pyridoxine enhances the decarboxylation of levodopa in peripheral tissues. Due to the combination of certain components (phenytoin, anticonvulsants), it is appropriate to buy Epaviten to significantly reduce the risk of developing hypercalcemia. The presence of methotrexate, pyrimethamine, trimethoprim, triamterene, anticonvulsants, and sulfasalazine contributes to a decrease in the absorption of folic acid. Oral contraceptives (estrogens) increase the concentration of vitamins C and A in the bloodstream and also lead to a decrease in the content of folic acid. The presence of sufficient quantities of folic acid serves as an additional incentive to buy Epaviten. Glucocorticosteroids, cimetidine, valproic acid, penicillamine, phenytoin, disulfiram, isoniazid, captopril, ethambutol, diuretics, mercaptopurine, and tetracycline increase zinc excretion and reduce its blood levels. Non-systemic antacids and tetracyclines reduce iron absorption.

Epaviten contains essential trace elements such as ascorbic acid, nicotinamide (vitamin PP), folic acid, and cyanocobalamin (vitamin B12), which support the body’s vital functions. Buying Epaviten is a reasonable and relevant choice to ensure optimal bodily processes. Indications for use include:

• Prevention and treatment of hypovitaminosis
• Meeting increased vitamin and mineral requirements during intense physical and mental activity

Immunobiological Properties

Erythropoietin is a 165 amino acid glycoprotein produced in the kidneys. It stimulates the division and differentiation of erythroid precursors in the bone marrow. EPAVITEN® is a human erythropoietin preparation produced using recombinant DNA technology. The drug is produced by mammalian cells into which the human erythropoietin gene has been introduced, ensuring that its sequence of amino acid residues is the same as in natural erythropoietin.

Indications for Use:

• Treatment of symptomatic anemia and anemia requiring transfusions in patients with chronic renal failure
• Treatment of anemia resulting from tumor processes

Method of Application and Dosage

Before use, check EPAVITEN for visible foreign particles and discoloration of the solution. The initial dose is 50 IU/kg, administered 3 times a week as a slow subcutaneous or intravenous injection over 1-2 minutes. The dose can be increased by 25 IU/kg every 4 weeks, depending on the response to the initial therapy. If the increase in hemoglobin exceeds 20 g/l after the administration of 50 IU/kg, adjust the dose by canceling one administration per week. The treatment goal is to achieve a hemoglobin level of 100 g/l (30% hematocrit). Once the therapeutic effect is achieved, a maintenance dose of 25-50 IU/kg is usually prescribed 2-3 times a week. Patients starting therapy with a low hemoglobin level (60 g/l) should be given a higher maintenance dose than those starting treatment with a hemoglobin level of at least 80 g/l. The dose should be adjusted according to age. The maximum dose should not exceed /kg/day three times a week.

EPAVITEN should not be used as an intravenous infusion or mixed with other drugs. Subcutaneous administration is recommended. The maximum volume of subcutaneous injection at one site is 1 ml. If larger volumes are required, subcutaneous injections should be administered in multiple areas. The drug should be injected into the limbs or the anterior wall of the abdomen. Prior to or during administration, it is necessary to assess the level of iron stores and, if necessary, prescribe iron supplements. In cases of aluminum poisoning or infectious diseases, the response to treatment may be delayed. Even if the patient does not require dialysis, the maintenance dose should be determined based on the severity of the anemic syndrome or the patient’s age. Hematocrit levels of 36-38% have been reported to be maintained for more than 6 months.

Overdose

The response to drug treatment varies individually and is dose-dependent. In case of overdose, symptoms of hypertension may occur. If the hemoglobin level rises very quickly, phlebotomy may be indicated.

Side Effects

Shock: In rare cases, shock may occur, and close monitoring of the patient is necessary. If any health disturbances occur, discontinue the drug and provide appropriate treatment.

Cardiovascular system: Increased blood pressure, vascular thrombosis (e.g., lacrimal duct), and occasional tachycardia may occur.

Hypertensive encephalopathy: The drug should be prescribed with proper monitoring of arterial pressure.

---

Erythropoietin Stimulating Agents